---
title: "Morning Trend | GRANDPHARMA tests new lows again, can the main line rebound from the pressure of negative factors in the sector?"
description: "On January 12th, GRANDPHARMA (0512.HK) fluctuated around the HKD 8 level throughout the day, with the pharmaceutical sector recently becoming a heavy area of capital outflow, and the market continues "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272239459.md"
published_at: "2026-01-13T01:00:00.000Z"
---

# Morning Trend | GRANDPHARMA tests new lows again, can the main line rebound from the pressure of negative factors in the sector?

> On January 12th, GRANDPHARMA (0512.HK) fluctuated around the HKD 8 level throughout the day, with the pharmaceutical sector recently becoming a heavy area of capital outflow, and the market continues to be under pressure. The company has no new product applications or favorable external mergers and acquisitions, resulting in a short-term "vacuum period." There were occasional surges during the trading session, but they were ultimately suppressed by short sellers, and the weak rebound could not break the pressure pattern. MACD, KDJ, and Bollinger Bands are all weakening, with a strong atmosphere of bottoming out in a sideways trend. Pharmaceutical policy regulation is tightening, and there are no significant new drugs or restructuring stimuli in the market. Mainstream capital is actively avoiding risks, and the overall sentiment is calm. Analysts believe that only a shift to looser policies or the restart of major projects will ignite a recovery market. Sudden mergers/acquisitions or drug progress during trading could signal short-term speculation; otherwise, there is sufficient downward momentum. Risk control: Pay attention to the movements of industry leaders and policy news, with a defensive approach to operations. Extreme trends may lead to a new round of declines due to capital bleeding

On January 12th, GRANDPHARMA (0512.HK) fluctuated around the HKD 8 mark throughout the day, as the pharmaceutical sector has recently become a heavy area of capital outflow, with the market remaining under pressure. The company has no new product applications or beneficial external mergers and acquisitions, resulting in a short-term "vacuum period." There were occasional upward movements during the trading session, but they were ultimately suppressed by short sellers, and the weak rebound could not break the pressure pattern. MACD, KDJ, and Bollinger Bands are all weakening, with a strong atmosphere of bottom-seeking in a sideways market.

With tightening pharmaceutical policy regulation and no significant new drugs or restructuring stimuli in the market, mainstream capital is actively avoiding risks, and the overall sentiment is calm. Analysts believe that only a shift towards looser policies or the restart of major projects will ignite a recovery market. Sudden mergers/acquisitions or drug progress during trading could signal short-term speculation; otherwise, there is sufficient downward momentum.

Risk control: Pay attention to the movements of industry leaders and policy news, with a focus on defensive operations. Extreme movements may lead to a new round of declines due to capital bleeding

### Related Stocks

- [00512.HK - GRANDPHARMA](https://longbridge.com/en/quote/00512.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| China's Drug Regulator Puts Hengrui Pharmaceuticals' SHR-1918 Injection in Priority Review | China's Drug Regulator Puts Hengrui Pharmaceuticals' SHR-1918 Injection in Priority Review | [Link](https://longbridge.com/en/news/276838200.md) |
| Sunshine Lake Pharma Wins NMPA Nod to Trial First China-Developed Nipah Virus Antibody | Sunshine Lake Pharma has received approval from China's Center for Drug Evaluation to begin clinical trials for HEC-648  | [Link](https://longbridge.com/en/news/276716153.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |
| Drugmaker Rovi's net profit rises on higher Okedi, heparin sales | Spanish drugmaker Laboratorios Farmaceuticos Rovi reported a 3% increase in net profit for 2025, reaching 140.4 million  | [Link](https://longbridge.com/en/news/276862604.md) |
| 08:53 ETTransMedia Group to Uplift Mental Health & Addiction Advocacy of TV Personality and Upcoming Author Jennifer Gaydos Hartman | TransMedia Group is set to amplify the advocacy of Jennifer Gaydos Hartman, a TV personality and author, as mental healt | [Link](https://longbridge.com/en/news/276744925.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.